Advertisement
Advertisement

CNTX

CNTX logo

Context Therapeutics Inc. Common Stock

0.47
USD
Sponsored
+0.01
+2.98%
Aug 11, 15:59 UTC -4
Closed
exchange

After-Market

0.47

0.00
+0.90%

CNTX Earnings Reports

Positive Surprise Ratio

CNTX beat 9 of 18 last estimates.

50%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.10
Implied change from Q2 26 (Revenue/ EPS)
--
/
-33.33%
Implied change from Q3 25 (Revenue/ EPS)
--
/
--

Context Therapeutics Inc. Common Stock earnings per share and revenue

On Aug 05, 2026, CNTX reported earnings of -0.15 USD per share (EPS) for Q2 26, missing the estimate of -0.09 USD, resulting in a -59.40% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -27.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an decrease of -33.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Actinium Pharmaceuticals, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.22
Actual
$0.89
Surprise
+502.71%
logo
Kiora Pharmaceuticals, Inc. Common Stock
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.34
Surprise
+46.24%
logo
AIM ImmunoTech Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.43
Surprise
-150.44%
logo
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
logo
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
logo
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-
Actual
-$0.26
Surprise
-
logo
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
logo
Minerva Neurosciences, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.17
Surprise
-44.93%
logo
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
logo
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
For Q2 2026, Context Therapeutics Inc. Common Stock reported EPS of -$0.15, missing estimates by -59.4%, and revenue of $0.00, 0% as expectations.
The stock price moved down -27.27%, changed from $0.69 before the earnings release to $0.50 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 10 analysts, Context Therapeutics Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement